ASTCT Pharmacy SIG Journal Club - March 2026

The ASTCT Pharmacy SIG March 2026 Journal Club will air on Wednesday, March 25 at 2 p.m. CT/3 p.m. ET. The webinar consisted of two, 30-minute journal club presentations, which included 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the March Journal Club session, Drs. Eckstein-Schoemann and Swartz will present two articles related to:

• Orca-T versus allogeneic HCT
• Teclistamab plus daratumumab in relapse or refractory multiple myeloma

Presenters & Articles:

Katarina Eckstein-Schoemann, PharmD

PGY-2 Pharmacy Resident

Duke University Hospital

Article: Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Cole Swartz, PharmD

PGY-2 Pharmacy Resident

The John Hopkins Hospital - Department of Pharmacy

Article: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Review current standard graft-versus-host disease (GVHD) prophylaxis following matched-donor allogeneic hematopoietic stem cell transplant (HSCT) and their limitations
• Analyze the efficacy and safety of Orca-T versus tacrolimus/methotrexate in the phase 3 PRECISION-T trial, with focus on chronic GVHD-free survival and non-relapse mortality
• Discuss the potential clinical role of Orca-T, including patient selection, logistical considerations, and implications for future GVHD prophylaxis
• Describe the rationale for combining teclistamab with daratumumab in relapsed/refractory multiple myeloma
  
• Analyze the safety and efficacy of teclistamab-daratumumab when used for relapsed/refractory multiple myeloma
• Identify appropriate candidates for teclistamab-daratumumab combination therapy based on prior treatment exposure, performance status, and disease characteristics

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this session will be available soon.